Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
45 Cards in this Set
- Front
- Back
Grading
|
Evaluate appearance and maturity of malignant tumor cells
|
|
Grade I
|
Tumor cells are well differentiated and have a close resemblance to tissue of origin. (Best prognosis)
|
|
Grade II
|
Tumor cells are moderately differentiated and have less resemblance to tissue of origin; with more variation in size and shape of tumor cells with increased mitosis
|
|
Grade III
|
Tumor cells are poorly to very poorly differentiated and have a remote resemblance to tissue of origin; with marked variation in shape and size of tumor and have greatly increased mitosis
|
|
Grade IV
|
Tumor cells are very poorly differentiated and have little to no resemblance to tissue of origin; with extreme variation in size and shape (Poorest prognosis)
|
|
Staging
|
Evaluates the size or spread of malignant tumor(s)
|
|
Tumor: T0
|
No evidence of tumor
|
|
Tumor: Tis Stage I
|
Carcinoma in situ indicates tumor is in a defined location shows no invasion into surrounding tissues
|
|
Tumor: T1, T2, T3, T4 Stage II
|
Primary tumor size and extent of local invasion; where T1 is small width minimal invasion and T4 is large with extensive local invasion into surrounding organs and tissue
|
|
Node: N0
|
Regionally lymph nodes show no abnormalities
|
|
Node: N1, N2, N3, N4 Stage III
|
Degree of lymph node involvement and spread to regional lymph nodes; where N1 is less involvement with minimal spreading and N4 is more involvement with extensive spreading
|
|
Metastasis: M0
|
No evidence of metastasis
|
|
Metastasis: M1 Stage IV
|
Indicates metastasis
|
|
Chemotherapy
|
Uses an antineoplastic drug or combination of such drugs into a standardized treatment regimen.
|
|
How Chemotherapy works
|
works by killing cells that divide rapidly
|
|
dose-dense chemotherapy
|
drugs are given with less time between treatments than in a standard chemotherapy treatment plan
|
|
Internal radiation (Brachytherapy)
chemotherapy administration |
Radiation treatment where the radiation source is placed inside the body or next to the area requiring treatment
|
|
External therapy (Teletherapy)
|
Most common form of radiation therapy. Involves pointing a radiation source from outside the body directly at the area of the body to be treated
|
|
Types of Surgery used in cancer
|
Preventative, Diagnostic, Staging, Curative, Debulking, Palliative, Supportive, Restoration
|
|
Preventative Surgery
|
Used to remove precancerous tissue
|
|
Diagnostic Surgery
|
Used to remove tissue for examination to determine if cancer is present
|
|
Staging Surgery
|
Used to determine the extend and amount of cancer
|
|
Curative Surgery
|
Used to remove the tumor when it appears that the cancer is confined to one location
|
|
Debulking Surgery
|
Used to remove as much of a tumor as possible and then treating the remaining disease with chemotherapy and radiation therapy
|
|
Palliative Surgery
|
Used to ease the complications of advance disease but not intended to cure the disease
|
|
Supportive Surgery
|
Used to help assist with the treatment of the disease
|
|
Restorative Surgery
|
Used to restore a person's appearance, or the function of an organ or body part after the primary surgary
|
|
Preventative Surgery Synonym
|
Prophylactic Surgery
|
|
Debulking Surgery Synonym
|
Cytoreductive Surgery
|
|
Restorative Surgery Synonym
|
Reconstructive Surgery
|
|
Incisional Biopsy
|
involves removing a portion or a sample of tissue from the tumor
|
|
Excisional Biopsy
|
is the attempted removal of the entire tumor
|
|
Tumor Markers
|
Substances, usually proteins, found in blood, urine and tissues that indicate the presence of cancer
|
|
Tumor Marker Examples
|
Prostate Specific Antigen (PSA); CA-125; Her2/neu; Carcinoembryonic Antigen (CEA); Beta-2 microglobulin (B2M)
|
|
Prostate Specific Antigen (PSA)
Tumor Marker |
Indicates the presence of prostatic cancer
|
|
CA-125
Tumor Marker |
used to identify ovarian cancer
|
|
Her2/neu
Tumor Marker |
associated with breast cancer
|
|
Carcinoembryonic Antigen (CEA)
Tumor Marker |
associated with colorectal, breast, pancreatic, lung, thyroid, live, cervix and bladder cancers
|
|
Beta-2 microglobulin (B2M)
|
associated with myelomas and lymphomas
|
|
Mohs Surgery
|
Most effective surgery for treating most types of skin cancer
|
|
Mohs Surgery Defined
|
Remove cancerous skin tissue layer by layer; examine microscopically until sample is free of disease
|
|
Antineoplastic
|
Acts by killing rapidly dividing cells. Trade name: Herceptin
|
|
Antimetabolite
|
Halts cell growth and cell division. Trade name: Xeloda
|
|
Immunosuppressive
|
Inhibit or prevent activity of the immune system. Trade Name: Purinethol
|
|
Immunostimulant
|
Stimulates the immune system by inducing activation or increasing activity. Trade name: Mozobil
|